IMed Consultancy explores the pros and cons of the regulatory scenario in key international markets within a changing regulatory environment

IMed Consultancy, a rising regulatory and compliance consultancy provider with over 50 years of experience supporting UK and international medical device and invitro device manufacturers launch and maintain their products on global markets, presents a guide to market entry looking at the EU, the UK and the USA. The whitepaper, available here: https://imedconsultancy.com, looks at these three major markets for medical devices, highlighting some key considerations relating to entering each of these geographies “first” to help manufacturers make informed decisions.

In today’s rapidly evolving landscape of healthcare and technology, navigating the realm of regulatory compliance for medical devices has become an increasingly complex endeavour. With advancements in medical technology, the development and deployment of innovative devices have brought forth immense opportunities for improving patient care and revolutionizing the healthcare industry. At the same time, however, major markets such as Europe and the UK are experiencing unprecedented regulatory shake-ups in the form of the introduction of the new EU MDR and IVDR and the Future UK Regulatory System.

These regulations aim to safeguard patient safety, ensure device effectiveness, and maintain ethical standards throughout the product lifecycle, from design and manufacturing to post-market surveillance. However, achieving regulatory compliance in this intricate landscape is no simple task. It requires a deep understanding of the evolving regulatory landscape, meticulous planning, robust quality management systems, and effective risk assessment strategies.

“Manufacturers and stakeholders must navigate through a web of complex standards, guidelines, and country-specific regulations before they decide which markets will be the most profitable to enter and which ones they should tackle first, laying the groundworks for further expansion in the most time-efficient and cost-effective way possible. We felt the need to try and untangle some of this web for them, to ease their decision process and to hopefully shed some light on the different opportunities these areas have to offer.” comments Leeanne Baker, Managing Director and Quality & Regulatory Consultant.

This article was written by Medilink Midlands Member, IMed Consultancy. For more information on Medilink Midlands Membership, click here

Latest Opportunities

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

UKRI unveils new £9 million proof-of-concept fund

The UKRI Proof of Concept funding opportunity aims to support and accelerate the development of…

Peer advice on “demand forecasting strategies”

An established Midlands-based health manufacturer is keen to hear from others about their demand forecasting…

Latest News

Illuminating biology: Advanced imaging and computational techniques transforming medical research at the University of Warwick

Advances in imaging and computational techniques are enabling researchers to discover more than ever before…

From firefighting to future-proofing: Why predictive compliance is key in medical device software

By Medilink Midlands Member Coauthor by Hindsight In today’s fast-paced and highly regulated world of…

IMed Consultancy new whitepaper reveals how to transform gruelling PMS procedures into commercial benefit

IMed Consultancy’s new free whitepaper, “PMS from pain to potential: more than just ticking a…